 |
|
RESEARCH LETTERS
Pimecrolimus Cream, 1%, vs Hydrocortisone Acetate Cream, 1%, in the Treatment of Facial Seborrheic Dermatitis: A Randomized, Investigator-Blind, Clinical Trial
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Seborrheic dermatitis is a chronic relapsing skin disorder that presents with erythema, scaling, and pruritus. It is estimated that between 3% and 5% of the population worldwide are affected by seborrheic dermatitis.1 Recent studies have shown the efficacy of pimecrolimus in treating facial seborrheic dermatitis.2-5 The purpose of this study was to compare the safety and efficacy of topical pimecrolimus with hydrocortisone acetate in the treatment of patients with facial seborrheic dermatitis.
Methods
This randomized, investigator-blind, controlled clinical trial was approved by the ethics committee of the Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences (A.F., A.S., F.G., and Y.D.) and was carried out from January to July 2005 at the Razi Skin Hospital (M.D., K.B., and K.F.), Tehran, Iran, on 40 patients with a diagnosis of facial seborrheic dermatitis. Patients with malignant or active viral lesions on the face and those who had . . . [Full Text of this Article]
Results
Comment
AUTHOR INFORMATION
Alireza Firooz, MD;
Amirreza Solhpour, MD;
Farzam Gorouhi, MD;
Maryam Daneshpazhooh, MD;
Kamran Balighi, MD;
Khalil Farsinejad, MD;
Mehdi Rashighi-Firoozabadi, MD;
Yahya Dowlati, MD, PhD
|
